2025-10-20 – Press Releases – www.prnewswire.com
BERLIN, Oct. 20, 2025 /PRNewswire/ — At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma…
